Published in Structure on December 09, 2009
cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev (2010) 3.27
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol (2012) 1.26
Cyclic GMP controls Rhodospirillum centenum cyst development. Mol Microbiol (2011) 1.18
The orphan histidine protein kinase SgmT is a c-di-GMP receptor and regulates composition of the extracellular matrix together with the orphan DNA binding response regulator DigR in Myxococcus xanthus. Mol Microbiol (2012) 0.91
Assembling the components of the quorum sensing pathway in African trypanosomes. Mol Microbiol (2015) 0.91
Laboratory-evolved mutants of an exogenous global regulator, IrrE from Deinococcus radiodurans, enhance stress tolerances of Escherichia coli. PLoS One (2011) 0.89
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors. J Biol Chem (2012) 0.86
De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions. Am J Hum Genet (2016) 0.86
Structures of the PelD cyclic diguanylate effector involved in pellicle formation in Pseudomonas aeruginosa PAO1. J Biol Chem (2012) 0.85
Colony-morphology screening uncovers a role for the Pseudomonas aeruginosa nitrogen-related phosphotransferase system in biofilm formation. Mol Microbiol (2015) 0.82
The N terminus of phosphodiesterase TbrPDEB1 of Trypanosoma brucei contains the signal for integration into the flagellar skeleton. Eukaryot Cell (2010) 0.82
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis (2014) 0.81
A universal stress protein (USP) in mycobacteria binds cAMP. J Biol Chem (2015) 0.81
Characterization of conformational changes and protein-protein interactions of rod photoreceptor phosphodiesterase (PDE6). J Biol Chem (2012) 0.80
Internal sense of direction: sensing and signaling from cytoplasmic chemoreceptors. Microbiol Mol Biol Rev (2014) 0.77
Sensor-response regulator interactions in a cross-regulated signal transduction network. Microbiology (2015) 0.77
Cyclic nucleotide binding and structural changes in the isolated GAF domain of Anabaena adenylyl cyclase, CyaB2. PeerJ (2015) 0.76
Dcsbis (PA2771) from Pseudomonas aeruginosa is a highly active diguanylate cyclase with unique activity regulation. Sci Rep (2016) 0.75
Genetic Modulation of c-di-GMP Turnover Affects Multiple Virulence Traits and Bacterial Virulence in Rice Pathogen Dickeya zeae. PLoS One (2016) 0.75
Phosphodiesterase 6C, cGMP-specific cone alpha'. AFCS Nat Mol Pages (2011) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A (1998) 36.83
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev (2006) 6.75
Cyclic nucleotide research -- still expanding after half a century. Nat Rev Mol Cell Biol (2002) 4.16
The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci (1997) 4.10
Overview of PDEs and their regulation. Circ Res (2007) 3.42
Regulatory potential, phyletic distribution and evolution of ancient, intracellular small-molecule-binding domains. J Mol Biol (2001) 2.68
Structure of the GAF domain, a ubiquitous signaling motif and a new class of cyclic GMP receptor. EMBO J (2000) 2.64
Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res (2003) 2.39
Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem (1982) 2.12
The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A (2002) 2.10
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J (2003) 1.56
Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. Proc Natl Acad Sci U S A (1990) 1.55
Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci U S A (2005) 1.40
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci U S A (2009) 1.30
Intrinsically disordered gamma-subunit of cGMP phosphodiesterase encodes functionally relevant transient secondary and tertiary structure. Proc Natl Acad Sci U S A (2008) 1.30
Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J Biol Chem (1996) 1.26
Molecular organization of bovine rod cGMP-phosphodiesterase 6. J Mol Biol (2001) 1.16
Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase. J Biol Chem (2004) 1.16
The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change. J Biol Chem (2008) 1.15
Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem (2004) 1.12
An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem (1995) 1.08
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem (2005) 1.06
cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem (2005) 1.04
Direct interaction of the inhibitory gamma-subunit of Rod cGMP phosphodiesterase (PDE6) with the PDE6 GAFa domains. Biochemistry (2002) 1.02
Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem (2002) 1.01
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem (2008) 1.01
Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem (2008) 0.99
The GAFa domains of rod cGMP-phosphodiesterase 6 determine the selectivity of the enzyme dimerization. J Biol Chem (2003) 0.97
Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms. J Struct Biol (2002) 0.95
Structural features of the noncatalytic cGMP binding sites of frog photoreceptor phosphodiesterase using cGMP analogs. J Biol Chem (1998) 0.92
Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem (1999) 0.92
Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. J Biol Chem (2008) 0.90
N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry (2007) 0.90
Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5. FEBS Lett (2003) 0.89
A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol (2006) 0.87
Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme. J Biol Chem (2006) 0.85
Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity. Biochem J (2009) 0.85
Changes in purine specificity in tandem GAF chimeras from cyanobacterial cyaB1 adenylate cyclase and rat phosphodiesterase 2. FEBS J (2007) 0.79
Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell (2005) 4.78
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med (2014) 4.70
E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat Struct Mol Biol (2007) 3.72
UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature (2011) 3.40
A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination. Mol Cell (2006) 3.30
Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet (2010) 2.76
Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc Natl Acad Sci U S A (2011) 2.11
Structure of an E3:E2~Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol Cell (2012) 2.07
Activation of the bacterial sensor kinase PhoQ by acidic pH. Mol Cell (2007) 1.98
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem (2003) 1.97
E2s: structurally economical and functionally replete. Biochem J (2011) 1.64
RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim Biophys Acta (2013) 1.64
Metal bridges between the PhoQ sensor domain and the membrane regulate transmembrane signaling. J Mol Biol (2005) 1.61
OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Mol Cell (2012) 1.58
Solid-state NMR and SAXS studies provide a structural basis for the activation of alphaB-crystallin oligomers. Nat Struct Mol Biol (2010) 1.53
Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome. Am J Hum Genet (2013) 1.50
Ubiquitin in motion: structural studies of the ubiquitin-conjugating enzyme∼ubiquitin conjugate. Biochemistry (2011) 1.46
Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci U S A (2007) 1.40
N-terminal domain of alphaB-crystallin provides a conformational switch for multimerization and structural heterogeneity. Proc Natl Acad Sci U S A (2011) 1.36
Following Ariadne's thread: a new perspective on RBR ubiquitin ligases. BMC Biol (2012) 1.33
Activity-enhancing mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis. Proc Natl Acad Sci U S A (2013) 1.32
alphaB-crystallin: a hybrid solid-state/solution-state NMR investigation reveals structural aspects of the heterogeneous oligomer. J Mol Biol (2008) 1.31
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem (2013) 1.28
Identification of an unconventional E3 binding surface on the UbcH5 ~ Ub conjugate recognized by a pathogenic bacterial E3 ligase. Proc Natl Acad Sci U S A (2010) 1.20
The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change. J Biol Chem (2008) 1.15
E2~Ub conjugates regulate the kinase activity of Shigella effector OspG during pathogenesis. EMBO J (2014) 1.14
Ubiquitin transfer from the E2 perspective: why is UbcH5 so promiscuous? Cell Cycle (2006) 1.12
Dynamic interactions of proteins in complex networks: identifying the complete set of interacting E2s for functional investigation of E3-dependent protein ubiquitination. FEBS J (2009) 1.06
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem (2007) 1.06
One size does not fit all: the oligomeric states of αB crystallin. FEBS Lett (2013) 1.04
The acidic transcription activator Gcn4 binds the mediator subunit Gal11/Med15 using a simple protein interface forming a fuzzy complex. Mol Cell (2011) 1.02
Structural insights into the conformation and oligomerization of E2~ubiquitin conjugates. Biochemistry (2012) 1.02
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem (2014) 1.01
Structural and functional characterization of the monomeric U-box domain from E4B. Biochemistry (2010) 1.01
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem (2008) 1.01
The PhoQ histidine kinases of Salmonella and Pseudomonas spp. are structurally and functionally different: evidence that pH and antimicrobial peptide sensing contribute to mammalian pathogenesis. Mol Microbiol (2008) 0.97
Synthesis and structure based optimization of novel Akt inhibitors. Bioorg Med Chem Lett (2008) 0.97
Engineering a ubiquitin ligase reveals conformational flexibility required for ubiquitin transfer. J Biol Chem (2009) 0.94
Activation of UbcH5c~Ub is the result of a shift in interdomain motions of the conjugate bound to U-box E3 ligase E4B. Biochemistry (2013) 0.94
Design of selective, ATP-competitive inhibitors of Akt. J Med Chem (2010) 0.93
Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. J Med Chem (2002) 0.90
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem (2015) 0.89
Mechanism of DNA binding by the ADR1 zinc finger transcription factor as determined by SPR. J Mol Biol (2003) 0.87
The essential Ubc4/Ubc5 function in yeast is HECT E3-dependent, and RING E3-dependent pathways require only monoubiquitin transfer by Ubc4. J Biol Chem (2011) 0.87
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett (2005) 0.86
Potent, selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg Med Chem Lett (2006) 0.86
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. Bioorg Med Chem Lett (2003) 0.84
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. Bioorg Med Chem Lett (2003) 0.84
The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene. Protein Sci (2007) 0.83
Biochemical and structural characterization of the ubiquitin-conjugating enzyme UBE2W reveals the formation of a noncovalent homodimer. Cell Biochem Biophys (2013) 0.83
PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency. Bioorg Med Chem Lett (2013) 0.82
The ubiquitin-conjugating enzyme, UbcM2, is restricted to monoubiquitylation by a two-fold mechanism that involves backside residues of E2 and Lys48 of ubiquitin. Biochemistry (2014) 0.82
Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences. J Biol Chem (2008) 0.81
RING-between-RINGs--keeping the safety on loaded guns. EMBO J (2012) 0.80
Structural Biology: Parkin's Serpentine Shape Revealed in the Year of the Snake. Curr Biol (2013) 0.80
Structural and kinetic characterization of the simplified SH3 domain FP1. Protein Sci (2003) 0.79
Identification and structural determination of the M(3) muscarinic acetylcholine receptor basolateral sorting signal. J Biol Chem (2005) 0.79
Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. J Med Chem (2012) 0.79
Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators. J Med Chem (2013) 0.77
Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett (2002) 0.77
Backbone 1H, 13C, and 15N resonance assignment of the 46 kDa dimeric GAF A domain of phosphodiesterase 5. J Biomol NMR (2005) 0.77
Flavonoid regulation of HCN2 channels. J Biol Chem (2013) 0.77
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. Bioorg Med Chem Lett (2013) 0.77
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. Bioorg Med Chem Lett (2013) 0.76
6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors. Bioorg Med Chem Lett (2011) 0.76
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett (2007) 0.76
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. J Med Chem (2011) 0.75
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase. J Med Chem (2005) 0.75